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Abstract
The EglN2/PHD1 prolyl hydroxylase is an important oxygen sensor
contributing to breast tumorigenesis. Emerging studies suggest
that there is functional cross talk between oxygen sensing and
mitochondrial function, both of which play an essential role for
sustained tumor growth. However, the potential link between
EglN2 and mitochondrial function remains largely undefined.
Here, we show that EglN2 depletion decreases mitochondrial
respiration in breast cancer under normoxia and hypoxia, which
correlates with decreased mitochondrial DNA in a HIF1/2a-
independent manner. Integrative analyses of gene expression
profile and genomewide binding of EglN2 under hypoxic condi-
tions reveal nuclear respiratory factor 1 (NRF1) motif enrichment
in EglN2-activated genes, suggesting NRF1 as an EglN2 binding
partner. Mechanistically, by forming an activator complex with
PGC1a and NRF1 on chromatin, EglN2 promotes the transcription
of ferridoxin reductase (FDXR) and maintains mitochondrial func-
tion. In addition, FDXR, as one of effectors for EglN2, contributes
to breast tumorigenesis in vitro and in vivo. Our findings suggest
that EglN2 regulates mitochondrial function in ERa-positive
breast cancer.
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Introduction
The presence of hypoxic cells in the tumor microenvironment was
proposed by Thomlinson and Gray more than 50 years ago
(Thomlinson & Gray, 1955). These hypoxic cells confer radio- or
chemotherapeutic resistance and therefore are hypothesized to be
under selection for aggressive malignancy during the course of
cancer development (Brown & Wilson, 2004). One central question
is how hypoxic cancer cells sense their oxygen availability, adapt to
the stressful environment, and proliferate out of control. The key
proteins mediating oxygen sensing in these cells mainly involve
proteins that are responsible for the hydroxylation of hypoxia-
inducible factor (HIF), namely the prolyl hydroxylases EglN1-3. As a
key EglN enzyme substrate, HIF1a is hydroxylated on prolines 402
and 564 under normoxic conditions. This promotes the binding of
HIF1a to the von Hippel–Lindau (VHL) E3 ligase complex, leading to
its subsequent ubiquitylation and proteasomal degradation (Kaelin &
Ratcliffe, 2008). Under hypoxia, EglNs lose their ability to hydroxy-
late HIF1a and HIF2a. This leads to HIFa stabilization and dimeriza-
tion with HIF1b (ARNT), thereby activating transcription of many
key genes involved in cell proliferation, metabolism, and angiogene-
sis (Semenza, 2012). Therefore, EglNs couple oxygen availability to
the transcription of many genes linked to hypoxic adaptation.
About a century ago, Otto Warburg proposed that unlike normal
cells, cancer cells have the tendency to utilize glycolysis to produce
ATP in the presence of oxygen, termed “aerobic glycolysis”
(Warburg et al, 1924). The central idea of the Warburg theory is the
transition from mitochondria-mediated oxidative phosphorylation to
a glycolytic metabolism in cancer cells (Warburg, 1925). However,
tumor cells mostly maintain intact mitochondria, and increasing
experimental evidence suggests that mitochondria still play important
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functions in cancer cells for sustained tumor growth (Nakashima
et al, 1984; Guppy et al, 2002; Gatenby & Gillies, 2004; Zu & Guppy,
2004; Moreno-Sanchez et al, 2007; Weinberg et al, 2010; Guo et al,
2011, 2013; Wallace, 2012; Strohecker et al, 2013). Chandel and
colleagues recently showed that mitochondrial metabolism is essen-
tial for oncogenic Ras-induced tumorigenicity (Weinberg et al, 2010).
In support of this finding, recent studies showed that autophagy
sustains mitochondrial metabolism that is important for oncogenic
Ras- or Raf-mediated tumorigenicity (Guo et al, 2011; Strohecker &
White, 2014). In addition, glutamine-mediated oxidative phosphory-
lation was reported to be a major ATP production resource under
either normoxia or hypoxia (Fan et al, 2013). From the therapeutic
perspective, recent studies implicated metformin, a mitochondrial
complex I inhibitor, as an attractive therapeutic agent in cancer ther-
apy (Owen et al, 2000; Zakikhani et al, 2006; Bost et al, 2012;
Pollak, 2012; Sanchez-Alvarez et al, 2013; Wheaton et al, 2014).
Collectively, these studies suggest mitochondrial inhibitors to be
promising treatment modalities for cancer, either alone or in combi-
nation with other therapies.
There are emerging studies clarifying the functional link
between oxygen sensing, mitochondrial function, and metabolism
(Papandreou et al, 2006; Simon, 2006; Zhang et al, 2007; Aragones
et al, 2008). For example, HIF1a was shown to repress mitochon-
drial biogenesis or cellular respiration via regulating c-Myc activity
and pyruvate dehydrogenase kinase 1 (PDK1) expression (Kim et al,
2006; Papandreou et al, 2006; Zhang et al, 2007). However, the role
of EglN family members, which serve as direct oxygen sensors, on
mitochondrial function remains largely undefined in cancer. Previ-
ous studies from our group, as well as others, showed that EglN2
mRNA levels are induced by estrogen and are higher in ERa-positive
breast cancer compared to ERa-negative breast cancer (Seth et al,
2002; Appelhoff et al, 2004; Zhang et al, 2009). Depletion of EglN2
decreases cell proliferation and breast tumorigenesis in an orthotopic
breast cancer model by diminishing cyclin D1 transcription (Zhang
et al, 2009). However, it remains largely unknown whether in
breast cancer cells there is a functional link between EglN2 and
mitochondria and if so, what is the underlying mechanism regulating
the effect of EglN2 on mitochondrial function?
In this study, we show that EglN2 depletion causes diminished
mitochondrial respiration in a HIF1/2a-independent manner,
resulting partly from decreased mtDNA content in breast cancer cells.
Our integrative analyses of EglN2 ChIP-Seq and gene expression profil-
ing under hypoxic conditions unveil a unique NRF1 motif enrich-
ment in EglN2-upregulated genes. Mechanistically, by forming an
activator complex with PGC1a and NRF1 on chromatin, EglN2
promotes FDXR gene expression and regulates mitochondrial func-
tion in a PGC1a- and NRF1-dependent manner. FDXR, as an impor-
tant downstream target of NRF1 and EglN2 signaling, at least
partially mediates the effect of EglN2 on mtDNA content and contri-
butes to tumorigenesis in ERa-positive breast cancer.
Results
EglN2 affects mitochondrial function in breast cancer
Our previous research demonstrated that EglN2 was critical to medi-
ate ERa-positive breast tumorigenesis (Zhang et al, 2009). Emerging
literature suggests that in cancer cells, in addition to shifts in glyco-
lytic activities, mitochondrial function also plays an important role
for sustained tumor growth (Nakashima et al, 1984; Guppy et al,
2002; Gatenby & Gillies, 2004; Zu & Guppy, 2004; Moreno-Sanchez
et al, 2007; Weinberg et al, 2010; Guo et al, 2011, 2013; Strohecker
et al, 2013). Furthermore, there exists the potential connection
between oxygen sensing and mitochondrial function (Zhang et al,
2007; Aragones et al, 2008). However, it remains unknown whether
there is a direct functional link between EglN2 and mitochondrial
function in cancer. To address this, we firstly used three indepen-
dent hairpins to deplete EglN2 expression in the ERa-positive breast
cancer cell line T47D as indicated by diminished EglN2 protein
(Fig 1A). Next, we examined the effect of EglN2 knockdown on
mitochondrial respiration, as measured by oxygen consumption rate
(OCR) with XF-24 extracellular flux analyzer. Breast cancer cells
depleted of EglN2 displayed impaired mitochondrial respiration
either under conditions of basal or maximal oxygen consumption
induced by FCCP treatment (Fig 1C). To validate the on-target effect
of EglN2 shRNA, we also rescued EglN2 knockdown by infecting
cells with an shRNA-resistant EglN2 overexpression construct
(Fig EV1A) and found that EglN2 overexpression rescued the
phenotype of EglN2 shRNA on OCR in these cells (Fig EV1B).
To explore further how EglN2 contributes to mitochondrial func-
tion in these cells, we examined two critical determinants of mito-
chondrial respiratory function, mitochondrial DNA (mtDNA), and
mitochondrial mass. To examine mtDNA content in these cells, we
isolated genomic DNA followed by qRT–PCR for several different
mtDNA markers, including D-Loop, Cox1, and mt-ND2. The amount
of these mtDNA markers was normalized against nuclear DNA
(nuDNA) to examine the relative abundance of mtDNA as described
previously (Moiseeva et al, 2009). Depletion of EglN2 by several
independent hairpins decreased mtDNA content in T47D cells
(Fig 1E), the effect rescued by overexpression of shRNA-resistant
EglN2 (Fig EV1C). In addition, the effect EglN2 on mtDNA content
was validated by the finding that EglN2 depletion led to decreased
protein expression for a subset of mitochondrial-encoded proteins,
such as mitochondrial complex I subunits mt-ND1, 2, and 5
(Fig EV1D), also some of mitochondrial complex IV subunits such
as COX1 but not COX2 or 3. On the other hand, we did not detect
distinctive difference in nuclear-encoded mitochondrial proteins
(NDUFA9, SDHA, and UQCRFS1) in some of these mitochondrial
complexes (Fig EV1D), indicating a potential mitochondrial–nuclear
protein imbalance upon EglN2 depletion. In addition to mtDNA
content, we used two independent hairpins against EglN2 and
examined their effect on mitochondrial mass in T47D cells. For this
purpose, we examined protein levels of several mitochondrial-
located proteins, including AIF, Bcl-XL, CLPP, cytochrome C, MCU,
mitofusin-1 and mitofusin-2, PDH, and VDAC, and found the
expression of these markers was not affected by EglN2 depletion
(Fig EV1E), which was further supported by the lack of change
for mitotracker green staining intensity upon EglN2 depletion
(Fig EV1F). Therefore, our data suggest that EglN2 depletion
decreases mtDNA content, but not mitochondrial mass, which is
consistent with finding that mtDNA depletion disrupted mitochon-
drial function and breast tumorigenesis without affecting mitochon-
drial mass (Holmuhamedov et al, 2003; Yu et al, 2007).
In a parallel set of experiments, we depleted EglN2 by two inde-
pendent hairpins in another ERa-positive breast cancer cell line
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Figure 1. EglN2 affects mitochondrial function in ERa-positive breast cancer cells.
A, B Immunoblot from T47D (A) or MCF-7 (B) cells infected with lentivirus encoding EglN2 shRNA (326, 327 or 328) or control shRNA (Ctrl).
C, D Measurement of oxygen consumption rate (OCR) in T47D (C) or MCF-7 (D) cells infected with lentivirus encoding EglN2 shRNAs or control shRNA (Ctrl shRNA) by
using the Seahorse XF24 extracellular flux analyzer.
E, F qRT–PCR quantification of mtDNA from T47D (E) or MCF-7 (F) cells infected with lentivirus encoding EglN2 shRNA (326, 327, or 328) or control shRNA.
G–I Immunoblot (G), measurement of OCR (H), and quantification of mtDNA (I) from T47D cells infected with lentivirus encoding FLAG-EglN2 (F-EglN2), FLAG-EglN2
H358A, or control (Ctrl).
Data information: Two-tailed Student’s t-test was used to examine the P-values from at least three replicate experiments. Error bars represent standard error of the
mean (SEM). *P < 0.05, **P < 0.01, and ***P < 0.005. See also Fig EV1.
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MCF-7 (Fig 1B). Consistently, EglN2 knockdown diminished mito-
chondrial respiration under basal or maximal oxygen consumption
condition in MCF-7 cells (Fig 1D). Depletion of EglN2 also
decreased mtDNA content in these cells, similarly as the phenotype
observed in T47D cells (Fig 1F). In a complementary set of experi-
ments, overexpression of EglN2 in T47D cells increased mitochon-
drial respiration (Fig 1G and H), corresponding to increased mtDNA
content in these cells (Fig 1I). It is important to note that the cata-
lytic dead EglN2 H358A mutant, as described previously (Epstein
et al, 2001; Zhang et al, 2009), increased mitochondrial respiration
and mtDNA content, indicating the effect of EglN2 on mtDNA is
independent of its enzymatic activity (Fig 1H and I).
To examine whether the effect of OCR is EglN2 specific, we also
depleted EglN1 or EglN3 expression by respective shRNAs and found
that OCR was not significantly affected by EglN1 or EglN3 under
maximal oxygen consumption condition (Fig EV1G and H). Under
basal condition, EglN3 depletion did not affect OCR but EglN1 deple-
tion modestly diminished OCR (Fig EV1H). Interestingly, depletion
of EglN1 or 3 led to modest upregulation of mtDNA, opposite to the
phenotype observed in EglN2-depleted cells (Fig EV1I). It is worth
noting that the effect of EglN2 on OCR and mtDNA is specific for
breast cancer cells tested, but not for murine embryonic fibroblast
(MEFs) as EglN2 knockout MEFs displayed similar OCR and mtDNA
content as the littermate wild-type control (Fig EV1J–L). Accumula-
tively, our data suggest that EglN2 positively regulates mitochondrial
function in ERa-positive breast cancer cells.
EglN2 regulates mitochondrial function in a HIF1/2a-
independent manner
Previous research showed that HIF1a repressed mitochondrial
biogenesis or cellular respiration via regulating c-Myc activity and
pyruvate dehydrogenase kinase 1 (PDK1) expression (Kim et al,
2006; Papandreou et al, 2006; Zhang et al, 2007). Although all of
EglN family members can hydroxylate HIFa in vitro, EglN1 remains
the dominant HIF prolyl hydroxylase regulating HIFa based on data
from cell culture and genetically engineered mice (Berra et al, 2003;
To & Huang, 2005; Takeda et al, 2006; Minamishima et al, 2008). To
examine whether EglN2 knockdown might decrease mitochondrial
function by inducing HIFa stabilization, we firstly determined HIF1a
and HIF2a protein levels upon EglN2 depletion in T47D and MCF-7
cells. In both cell lines, EglN2 depletion by multiple independent
shRNAs did not lead to HIF1a or HIF2a upregulation, which is
consistent with previously published data obtained with EglN2
siRNAs for MCF-7 cells (Fig 2A and B) (Appelhoff et al, 2004). This
finding suggests that EglN2 regulates mitochondrial function in a
HIF1/2a-independent manner. To further confirm this finding, we
generated MCF-7 cell lines depleted of HIF1a expression with two
independent hairpins (Fig 2C). Consistent with the previous publica-
tion, HIF1a depletion led to increased mtDNA content as well as
increased OCR (Figs 2D and EV2A) (Zhang et al, 2007). However,
EglN2 depletion still led to decreased OCR as well as mtDNA content
in these cells depleted of HIF1a, strengthening the notion that the
effect of EglN2 on mitochondrial function is independent of HIF1a
(Figs 2D and EV2A). In addition to HIF1a, we also depleted HIF2a in
these cells (Fig 2E) and found similarly that EglN2 knockdown
decreased mtDNA content and OCR independent of HIF2a (Figs 2F
and EV2B).
As a complementary approach, we also depleted the expression
of HIFa binding partner ARNT, which is essential for HIFa-mediated
transcriptional regulation machinery (Fig 2G). Similar to our find-
ings obtained from HIF1a or HIF2a knockdown cell lines, ARNT
depletion in MCF-7 cells also led to increased mtDNA content and
OCR (Figs 2H and EV2C). Consistently, EglN2 depletion was still
able to decrease mtDNA content and OCR in the cells depleted of
ARNT (Figs 2H and EV2C). To rule out the cell type-specific effect
of EglN2 on mitochondrial function in a HIFa-independent manner,
we also depleted either HIF1a, HIF2a, or ARNT in T47D cells
(Fig EV2D, F, and H). In accordance with the data we obtained from
MCF-7 cells, EglN2 depletion in these HIF knockdown cells still led
to decreased mtDNA content (Fig EV2E, G and I). In summary, our
data suggest that EglN2 regulates mitochondrial function in a HIF1/
2a-independent manner.
EglN2 binds to chromatin and regulates mitochondrial function
under hypoxia
Considering that most solid tumors are characterized by the
existence of hypoxic regions compared to normal tissues, we also
examined the effect of EglN2 on mtDNA contents under hypoxia.
Similar to the effects observed under normoxia, depletion of EglN2
by several independent hairpins decreased mtDNA content in both
T47D and MCF-7 cells under hypoxia (Fig 3A and B). Of note, deple-
tion of EglN2 showed modest but more consistent downregulation
of mtDNA content under hypoxia than normoxia (comparing Fig 3A
to 1C, Fig 3B to 1F). Consistent with the mtDNA phenotype, cells
depleted of EglN2 by two independent hairpins in both T47D and
MCF-7 showed decreased oxygen consumption rate under hypoxia
measured by an oxytherm electrode unit (Figs 3C and EV3A).
Conversely, EglN2 WT or catalytic dead (H358A) overexpression in
T47D cells increased mtDNA content under hypoxia, with higher
mtDNA induction compared to normoxia (compare Fig 3D to 1I,
average fourfold versus 1.5-fold). These EglN2-overexpressed cells
also displayed increased oxygen consumption rate compared to
control under hypoxia (Fig 3E). To determine whether EglN2 regu-
lates mitochondrial function via HIF under hypoxia, we also exam-
ined HIF1a, HIF2a, or ARNT protein levels upon EglN2 depletion in
T47D or MCF-7 cells (Fig EV3B and C). In MCF-7 cells, EglN2 deple-
tion did not affect any of these protein levels (Fig EV3B). In T47D
cells, EglN2 depletion led to downregulation of HIF1a and HIF2a
while not affecting ARNT protein levels (Fig EV3C), further arguing
against the involvement of HIFa in EglN2-depletion-induced OCR or
mtDNA downregulation since HIFa downregulation would increase
OCR or mtDNA content as described previously as well as in our
experiment system (Zhang et al, 2007). To further confirm this, we
also depleted HIF1a, HIF2a, or ARNT expression by using validated
shRNA used previously followed by examination of mtDNA content
by EglN2 depletion under hypoxia. Consistently, in both MCF-7 and
T47D cells, our results showed that EglN2 depletion led to decreased
mtDNA content in a HIF1/2a-independent manner under hypoxia
(Figs 3F and EV3D).
In order to determine the mechanism by which EglN2 contributes
to mitochondrial function, we treated T47D cells with various
hypoxic conditions (5 and 1%) followed by cell fractionations to
examine EglN2 protein levels in different cellular compartments.
Interestingly, not only was EglN2 localized in the cytoplasm and
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Figure 2. EglN2 regulates mitochondrial function in a HIF1/2a-independent manner.
A, B Immunoblot from T47D (A) or MCF-7 (B) cells infected with lentivirus encoding EglN2 shRNA (326, 327, or 328) or control shRNA (Ctrl).
C–H Immunoblot of cell lysates (C, E, G) and qRT–PCR quantification of mtDNA (D, F, H) from MCF-7 cells infected with lentivirus encoding either HIF1a shRNAs (3809,
3810) (C), HIF2a shRNA (3804) (E), ARNT shRNA (1770) (G), or control () followed by another infection with lentivirus encoding either EglN2 shRNA (326) or control
(Ctrl) shRNA.
Data information: Two-tailed Student’s t-test was used to examine the P-values from at least three replicate experiments. Error bars represent SEM. *P < 0.05,
**P < 0.01, ***P < 0.005. See also Fig EV2.
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nucleus as previously described (Metzen et al, 2003; Steinhoff et al,
2009; Fujita et al, 2012), but also EglN2 displayed increased chro-
matin-bound levels upon exposure to hypoxia (Fig 3G), raising the
possibility that EglN2 interacts with the chromatin and affects tran-
scriptional machinery. In order to test this possibility, we generated
mammalian expression plasmids encoding fusion proteins consist-
ing of the TET repressor DNA-binding domain (TETr) fused to
EglN2 (or CDK2 and E2F1 serving as negative and positive control,
respectively) with a flexible linker containing Gly4-Ser repeats as
described previously (Fig 3H) (Kim & Kaelin, 2001). Next, cells were
transiently transfected with plasmids encoding various TETr-fusion
proteins and a luciferase reporter containing seven TETo-binding
sites to examine the effect of fusion proteins on transcription
(Fig 3H). Consistent with previous literature, E2F1 dramatically
induced transcription while CDK2 fusion protein did not (Fig EV3E)
(Kim & Kaelin, 2001). EglN2 modestly induced transcription in a
dose-dependent manner (Fig EV3F). To examine whether the effect
of TETr-EglN2 on transcription was direct, we treated these cells
with doxycycline, which blocks the binding of TETr to TETo. Doxy-
cycline treatment abrogated the effect of EglN2 on transcriptional
activation (Fig EV3F). In addition, we treated cells with various
hypoxic conditions (5% and 1%) and found that EglN2 induced
more robust transcriptional activation under hypoxia compared to
normoxia in T47D or 293T cells, corresponding to increased EglN2
chromatin binding upon hypoxic treatment (Figs 3G and I, and
EV3G). Accumulatively, our results suggest that EglN2 activates
transcription, with more profound effect under hypoxia.
EglN2 binds to NRF1 and PGC1a complex on chromatin
Hypoxia is a vital determinant that affects gene expression during
tumor growth and progression. There is a close link between patho-
logically low oxygen levels and therapy-resistant tumors (Shannon
et al, 2003; Brown & Wilson, 2004). In addition, EglN2 shows a
more profound effect on mtDNA content as well as more robust
transcriptional activation under hypoxia compared to normoxia.
Therefore, we wondered whether the effect of EglN2 on mitochon-
dria has any connection with transcriptional activation of EglN2
under hypoxia in breast cancer. Since EglN2 binds to chromatin
robustly under hypoxic conditions, next we aimed to map the EglN2
binding sites on a genomewide scale. For this purpose, we
conducted HA-EglN2 ChIP-Seq in the T47D cells that overexpressed
HA-EglN2 and were cultured under hypoxic condition. T47D
parental cells treated with the same condition followed by HA ChIP-
Seq served as the control to filter non-specific binding. Consistent
with our hypothesis, EglN2 displayed robust chromatin binding with
32,382 binding peaks under false discovery rate (FDR) of 0.05, with
significant occurrence of binding sites observed at gene-proximal
promoters by CEAS analysis (Shin et al, 2009) (Fig 4A and
Table EV1).
To further examine the potential effect of EglN2 on downstream
target genes, we performed transcriptome microarray analysis using
an EglN2 siRNA or control siRNA followed by hypoxic treatment. A
total of 919 genes were differentially expressed upon EglN2 deple-
tion (Limma algorithm, P-value cutoff of e-05) (Smyth, 2004),
including 606 positively regulated and 313 negatively regulated
genes (Table EV2). For comparison, we also performed microarray
analysis under normoxia (Table EV3) and found that there are more
EglN2 positively regulated under hypoxia compared to normoxia
(Fig EV4A and B), consistent with more robust effect of EglN2 on
transcriptional activation under hypoxia (Figs 3I and EV3G). As
described above, we observed significant enrichment of EglN2 bind-
ing peaks on gene-proximal promoters (Fig 4A). To identify unique
transcription factors that regulate EglN2 target gene either positively
or negatively, we selected the strongest 1,000 EglN2 peaks within
promoters of EglN2 positively and negatively regulated genes
(P-value cutoff of 0.05) and performed motif enrichment analysis by
using the method described previously (He et al, 2010; Liu et al,
2011). We identified nuclear respiratory factor 1 (NRF1) motif
uniquely enriched in promoters of EglN2 positively regulated genes
(Fig 4B), suggesting that NRF1 and EglN2 might cooperate to acti-
vate transcription. In addition, depletion of NRF1 decreased
anchorage-independent growth, an important indicator for tumor
growth (Fig EV4C), which is reminiscent of the phenotype we
observed previously with EglN2 depletion in ERa-positive breast
cancer cells (Zhang et al, 2009). It is worth noting that the consensus
recognition motif for HIF1a and ARNT was enriched in the promoters
of both EglN2-activated and EglN2-repressed genes (Fig 4B). Since our
results showed that the effects of EglN2 on mitochondrial function
under normoxia or hypoxia were largely independent of HIF1/2a
▸Figure 3. EglN2 binds to chromatin and regulates mitochondrial function under hypoxia.A, B qRT–PCR quantification of mtDNA from T47D (A) or MCF-7 (B) cells infected with lentivirus encoding EglN2 shRNA (326, 327, or 328) or control shRNA and treated
with hypoxia (5% O2).
C Measurement of oxygen consumption by an oxytherm electrode unit as a function of time for T47D cells infected with lentivirus encoding EglN2 shRNA (326 or
327), or control shRNA and treated with hypoxia (5% O2).
D qRT–PCR quantification of mtDNA from T47D cells infected with lentivirus encoding FLAG-EglN2, FLAG-EglN2 H358A, or control (Ctrl) and treated with hypoxia (5% O2).
E Measurement of oxygen consumption by an oxytherm electrode unit as a function of time for T47D cells infected with lentivirus encoding FLAG-EglN2, FLAG-EglN2
H358A, or control (Ctrl) (E) treated with hypoxia (5% O2).
F qRT–PCR quantification of mtDNA from MCF-7 cells infected with lentivirus encoding HIF1a shRNA (3810), HIF2a shRNA (3804), ARNT shRNA (1770),
or control () followed by another infection with lentivirus encoding either EglN2 shRNA (326) or control (Ctrl) shRNA and treated with hypoxia
(5% O2).
G Immunoblot of fractionated cell lysates (WCE, cytoplasmic, nuclear soluble, and chromatin bound) from T47D (1 × 107) cells treated with hypoxia (5%, 1%) or
control ().
H Schematics of TETr-EglN2 and luciferase reporter plasmids.
I Determination of luciferase activity in T47D cells transfected with plasmids encoding the indicated TETr-fusion proteins along with the pUHC 13-3 reporter and a
CMV-Renilla plasmid followed by the indicated treatment.
Data information: Two-tailed Student’s t-test was used to examine the P-values from at least three replicate experiments. Error bars represent SEM. **P < 0.01,
***P < 0.005. See also Fig EV3.
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signaling, we focus our efforts on elucidating the role of NRF1 on
mitochondrial signaling affected by EglN2.
NRF1 was first identified as an activator for cytochrome C gene
involved in the mitochondrial respiratory chain (Evans & Scarpulla,
1989). As a key transcription factor of nucleus-encoded genes asso-
ciated with mitochondrial function, NRF1 affects various genes
(such as TFAM, TFB1M, and TFB2M) required for mitochondrial
respiratory functions by employing PGC1a as the essential transcrip-
tional co-activator (Kelly & Scarpulla, 2004; Scarpulla, 2006; Zhang
et al, 2007). Abnormally active mitochondrial function was known
to predict poor clinical outcome in human breast cancer patients
(Sotgia et al, 2012). Our results above showed that EglN2 regulated
mitochondrial function, which motivated us to examine the poten-
tial functional link between EglN2 and NRF1 in this process. We
first asked whether EglN2 and NRF1 directly interact in vitro by
performing glutathione S-transferase (GST) pull-down assays with
purified GST or GST-NRF1 and in vitro translated EglN2. As positive
controls, we interrogated the previously described interactions
between NRF1 and cyclin D1 as well as EglN2 and FOXO3a (Wang
et al, 2006; Zheng et al, 2014). We also observed the binding
between NRF1 and EglN2 (Fig 4C). Next, to examine the interaction
between EglN2 and NRF1 in cells, we treated T47D breast cancer
cells expressing HA-NRF1 under the control of a weak heterologous
promoter with normoxia or hypoxia followed by co-immunoprecipi-
tation. Whereas the interaction between NRF1 and EglN2 was weak
under normoxia, it was significantly enhanced under hypoxia
(Fig 4D). Consistently, we observed enhanced binding between
endogenous EglN2 and NRF1 in T47D or MCF-7 cells under hypoxia
(Fig 4E and F). Despite the robust upregulation of HIF1a protein
levels under hypoxia, we only detected minimal binding between
EglN2 and HIF1a (Fig 4E and F). This was further supported by
using another hypoxia mimetic, DMOG, which only modestly
induced endogenous EglN2 binding with HIF1a or NRF1 in some
setting (Fig 4E and F). The observation that the interaction between
NRF1 and EglN2 was not affected upon HIF1a depletion in these
cells under hypoxia (Fig EV4D) is consistent with HIF1a-independent
mitochondrial regulation by EglN2. To further examine whether
NRF1 and EglN2 binding is dependent on EglN2 enzymatic activity,
we also examined the binding of EglN2 H358A catalytic mutant with
NRF1 and found that the mutant bound to NRF1 similarly as the
wild type, arguing that this binding is independent of EglN2
enzymatic activity (Fig EV4E).
Our results suggest a potential link between hypoxia-induced
EglN2-NRF1 association and mitochondrial function in ERa-positive
breast cancer. Since PGC1a is the essential transcriptional co-
activator and binding partner of NRF1 that orchestrates mitochon-
drial function (Scarpulla, 2006), we postulated that hypoxia might
similarly induce EglN2 and PGC1a binding. To test this, we exam-
ined the interaction between EglN2 and PGC1a and observed
enhanced binding under hypoxia compared to normoxia (Fig 4E
and F). Similar to the binding between EglN2 and NRF1, the interac-
tion of EglN2 and PGC1a is independent of EglN2 enzymatic activity
(Fig EV4F). To further examine which cellular compartment where
EglN2 binds with NRF1 and PGC1a complex, we performed cell
fractionation followed by endogenous EglN2 immunoprecipitation
under either normoxia or hypoxia. Whereas EglN2 bound with
NRF1 and PGC1a weakly in chromatin-bound fractions under
normoxia, these interactions were significantly enriched under
hypoxia condition (Fig EV4G and H). Based on these findings, we
hypothesized that EglN2 might mediate the interaction between
PGC1a and NRF1, therefore affecting target gene expression
involved in modulating mitochondrial function (Murphy, 2009).
Indeed, EglN2 depletion dramatically decreased the association
between PGC1a and NRF1 (Fig 4G), suggesting that EglN2 plays an
important role mediating the PGC1a/NRF1 interaction. We further
examined mtDNA content in cells overexpressing EglN2 followed by
depletion of either NRF1 or PGC1a siRNA (Fig 4H and I). Under
hypoxic condition, the increase in mtDNA content upon EglN2 over-
expression was abrogated by either NRF1 or PGC1a knockdown
(Fig 4J), suggesting that the effect of EglN2 on mitochondrial func-
tion is NRF1- and PGC1a-dependent. It is notable that comparing to
single FLAG-EglN2-infected cells, this cell line with another round
of transfection with ctrl siRNA displayed less robust increase in
mtDNA content (comparing Fig 3D with Fig 4J), which could possi-
bly be due to the longer term culture of latter cells that develop
some adaptive response.
EglN2 regulates FDXR in breast cancer
To further identify the downstream effectors of EglN2 and NRF1/
PGC1a complex that might mediate the effect of EglN2 on mitochon-
drial function under hypoxia, we carried out NRF1 ChIP-Seq under
hypoxic condition in these cells and determined how EglN2 and
NRF1 interact on a genomewide scale. NRF1 ChIP-Seq analysis
▸Figure 4. EglN2 interacts with NRF1 and PGC1a.A Genomewide distribution of EglN2 binding peaks under hypoxia (1% O2) with concurrent DMOG (1 mM) treatment for 16 h.
B Motif enrichment of integrated analyses of gene expression profiling (Ctrl vs EglN2) and EglN2 binding peaks from T47D cells treated with DMOG (1 mM) and
hypoxia (1% O2) for 16 h.
C Immunoblot (IB) analysis showing the binding between in vitro translated EglN2 or cyclin D1 and GST, GST-NRF1, or GST-FOXO3a.
D Immunoblot (IB) assays of whole-cell extract (WCE) and immunoprecipitation (IP) of T47D (1 × 107) cells (expressing Ctrl or HA-NRF1) treated with either control
(normoxia) or hypoxia (5% O2).
E, F Immunoblot (IB) assays of whole-cell extract (WCE) and immunoprecipitation (IP) of T47D (E) or MCF-7 (F) (5 × 107) cells treated with either control (normoxia),
DMOG (1 mM), or hypoxia (5% O2).
G Immunoblot (IB) assays of whole-cell extracts (WCE) and immunoprecipitation (IP) of T47D (5 × 107) cells infected with lentivirus encoding either EglN2 shRNAs
(325 and 326) or control () followed by transfection with either HA-NRF1 or HA-empty control.
H–J qRT–PCR of mRNA (H and I) or mtDNA (J) from T47D cells infected with lentivirus encoding either FLAG-EglN2 or control (Ctrl) followed by transfecting with the
NRF1 pool siRNA (H), PGC1a siRNA #4 (I), or control siRNA (Ctrl) and hypoxia (5% O2) treatment.
Data information: Two-tailed Student’s t-test was used to examine the P-values from at least three replicate experiments. Error bars represent SEM. *P < 0.05,
**P < 0.01, ***P < 0.005. See also Fig EV4.
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demonstrated its binding sites predominantly located in the proxi-
mal promoter regions (Fig 5A and Table EV4) and largely over-
lapped with EglN2 binding sites (Fig 5B and Table EV5), reinforcing
the functional interaction between EglN2 and NRF1.
To identify the essential genes responsible for the effect of EglN2
and NRF1 on mitochondrial function under hypoxia, we selected
eight mitochondrial-related pathway genes that were bound by both
EglN2 and NRF1 on their promoters (Appendix Fig S1A–H) and
showed reduced expression upon EglN2 knockdown (Table EV2).
Consistent with the ChIP-Seq data, ChIP-PCR confirmed the binding
of endogenous EglN2 on their promoters (Fig 5C) under hypoxia. In
addition, EglN2 depletion decreased their expression in T47D cells
under hypoxia (Fig 5D and E). Similar findings were found for
MCF-7 cell under hypoxia (Fig 5F). In accordance with the data that
EglN2 bound with NRF1 weakly under normoxia and regulates
mitochondrial function, EglN2 depletion also decreased these gene
expressions under normoxia (Fig EV5A). Among these genes, FDXR
was the one showing the most robustly decreased expression upon
NRF1 depletion under normoxia or hypoxia in T47D cells (Figs 5G
and H, and EV5B), and also the most downregulated one upon
NRF1 knockdown in MCF-7 cells under hypoxia (Fig 5I). Therefore,
we hypothesized that FDXR may be one of essential downstream
effectors in EglN2/NRF1-regulated mitochondrial pathway. To this
end, we set to examine the role of FDXR in EglN2- and NRF1-
regulated mitochondrial phenotype in breast cancer cells. Consistent
with stronger binding of EglN2 on FDXR gene promoter under
hypoxia compared to normoxia, hypoxia treatment modestly upreg-
ulated FDXR mRNA expression in T47D cells (Fig EV5C). In addi-
tion, overexpression of EglN2 increased FDXR mRNA expression
and this effect was ameliorated upon NRF1 depletion (Fig 5J). Simi-
larly, depletion of PGC1a by siRNAs attenuated both basal and
EglN2-induced FDXR expression under hypoxia (Figs 5K and
EV5D). Collectively, these results suggest that NRF1 and PGC1a are
required for the regulation of FDXR by EglN2 and that an EglN2,
NRF1, and PGC1a complex is required for FDXR expression in
ERa-positive cancer.
FDXR contributes to ERa-positive breast tumorigenesis
FDXR is an important mitochondrial flavoprotein that initiates elec-
tron transport from NADPH to its substrates, which contributes to
p53-mediated apoptosis through the generation of oxidative stress in
mitochondria in colon cancer (Hwang et al, 2001). However, its role
in mitochondrial regulation and tumorigenesis in other cancers is
relatively unexplored. By serving as a key downstream target of
EglN2 and NRF1, FDXR may be essential for their ability to regulate
mtDNA content. To test this, first we depleted FDXR expression by
two independent shRNAs (FDXR sh434 or sh435, Fig 6A), and
indeed observed decreased mtDNA content compared with control
under hypoxia (Fig 6B). In accordance with FDXR acting down-
stream of EglN2 on mitochondrial signaling, FDXR overexpression
rescued the mtDNA defect induced by EglN2 loss (Fig 6C and D). By
examining oxygen consumption rate using the XF-24 extracellular
flux analyzer, we observed decreased basal oxygen consumption
upon EglN2 depletion, an effect rescued by FDXR overexpression
(Fig 6E). Next, we examined the anchorage-independent growth in
these cells, an important marker for tumor phenotype. Consistent
with our previously published data with orthotopic tumor growth,
EglN2 depletion decreased anchorage-independent growth (Fig 6F)
(Zhang et al, 2009). Overexpression of FDXR can at least partially
rescue EglN2 loss-induced soft agar growth defect (Fig 6F). These
results suggest that FDXR, as a downstream target of EglN2 and
NRF1, at least partially mediates the effect of EglN2 on mitochon-
drial function and anchorage-independent growth.
As a downstream effector of EglN2, we further examined the func-
tion of FDXR in ERa-positive breast tumorigenesis. To this end, we
generated T47D cells expressing firefly luciferase followed by infection
with lentivirus encoding either FDXR shRNAs (FDXR sh434 or sh435,
Fig 6A) or control. Firstly, cells depleted of FDXR by two different
shRNAs displayed a proliferation defect compared to control (Fig 6G).
Next, T47D FDXR knockdown (sh434 or sh435) and control cells were
orthotopically injected bilaterally into the mammary fat pads of mice
supplemented with estrogen pellets to promote the growth of breast
cancer cells followed by noninvasive bioluminescent imaging. The
initial imaging was taken at day 3 post-implantation of tumor cells to
verify equal injection on bilateral mammary glands, and further imag-
ing was performed on a weekly basis over 4 weeks. Over time, there
was a progressive decline in tumor bioluminescent signals from FDXR
shRNAs compared to control shRNA (Fig 6H and I). Consistent with
the bioluminescent signal, the tumors formed from FDXR shRNA cells
were significantly smaller than those formed from control shRNA cells
(Figures 6J and K), indicating that FDXR depletion inhibits breast
tumor growth in vivo.
To further examine the functional importance of FDXR in breast
cancer patients, we compared FDXR expression between ERa-
positive breast cancer versus normal breast samples in METABRIC
and TCGA breast cancer cohorts (Cancer Genome Atlas, 2012; Curtis
et al, 2012). In both datasets, FDXR expression was higher in cancer
cohorts than in normal cohorts (Figs 6L and EV5E). Finally, higher
expression of FDXR is associated with worse clinical prognosis in
ERa-positive breast cancer patients (Fig 6M), suggesting FDXR to be
a potential prognostic marker in ERa-positive cancer.
▸Figure 5. EglN2 and NRF1 regulate FDXR in ERa-positive breast cancer cells.A Genomewide distribution of NRF1 binding peaks under hypoxia (1% O2) with concurrent DMOG (1 mM) treatment for 16 h.
B Venn diagram showing the overlap between the EglN2 and NRF1 cistromes in T47D cells.
C qRT–PCR of genomic DNA retrieved from either control IgG (Ctrl) or EglN2 antibody ChIP under normoxia or hypoxia.
D–F Immunoblots of lysates (D), qRT–PCR of mRNA from T47D cells (E) or MCF-7 (F) transfected with EglN2 siRNA (1) and (4) or control (Ctrl) followed by hypoxia
treatment (5% O2).
G–I Immunoblots of lysates (G), qRT–PCR of mRNA from T47D (H) or MCF-7 (I) transfected with the NRF1 pool siRNA followed by hypoxia treatment (5% O2).
J, K qRT–PCR of mRNA from T47D cells infected with lentivirus encoding either FLAG-EglN2 or control (Ctrl) and, after selection, transfected with NRF1 siRNA (J), PGC1a
siRNA (K), or control siRNA (Ctrl) followed by hypoxia (5% O2) treatment for 16 h.
Data information: Two-tailed Student’s t-test was used to examine the P-values from at least three replicate experiments. Error bars represent SEM. ***P < 0.005.
See also Fig EV5.
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Discussion
In this study, we demonstrate that EglN2 contributes to maintenance
of mitochondrial function in ERa-positive breast cancer under
hypoxia. By integrative analyses of transcriptome profiles and geno-
mewide binding of EglN2 under hypoxic condition, we discovered
that EglN2 promotes transcriptional activation by interacting with
NRF1. Mechanistically, by forming an activator complex with PGC1a
and NRF1, EglN2 promotes FDXR gene expression and regulates
mitochondrial function in a PGC1a- and NRF1-dependent manner.
FDXR is a common downstream target of this trimeric protein
complex that at least partially mediates the effect of EglN2 on mito-
chondrial function. FDXR depletion decreases breast cancer cell
proliferation and xenograft growth in vivo. Increased FDXR expres-
sion also predicts worse prognosis in ERa-positive breast cancer.
EglN2 has previously been shown to be involved in reprogram-
ming metabolism pathways. Elimination of EglN2 decreases the
oxygen consumption in murine skeletal muscle by reprogramming
glucose metabolism from oxidative to anaerobic ATP production
through inducing a PPARa pathway (Aragones et al, 2008). Under
normal conditions, this will impair the skeletal muscle performance
since EglN2 knockout mice have lower oxygen consumption.
However, under ischemia injury condition, these mice displayed
reduced oxidative stress with less reaction oxygen species (ROS)
production. Therefore, these mice are more resistant to hypoxic
tolerance. Our study in breast cancer cells demonstrates depletion of
EglN2 decreases oxygen consumption rate, yet by a different mecha-
nism involving the PGC1a and NRF1 complex.
Mechanistically, we propose that EglN2 regulates FDXR and
modulates mitochondrial functions in breast cancer cells with more
profound effects under the hypoxic condition. Our integrative analy-
ses of EglN2 and NRF1 ChIP-Seq data, as well as EglN2-mediated
differential mRNA expression, identify genes potentially involved in
mitochondrial functions. Among these genes, FDXR is the most
robustly regulated genes by both EglN2 and NRF1 under normoxia
or hypoxia. It is important to note that there still exists the possibil-
ity that other gene may be involved in regulating the mitochondrial
function affected by EglN2/NRF1 under normoxia or hypoxia, which
was also reflected by the partial rescue of anchorage-independent
growth by FDXR overexpression in EglN2-depleted cells. Nonethe-
less, our findings establish FDXR as an important downstream
regulator for EglN2 and NRF1 that modulates mitochondrial
function in ERa-positive breast cancer.
EglN2 enzymatic activity depends on oxygen, and it is lower
under hypoxic than normoxic conditions. Under hypoxic conditions,
EglN2 depletion decreases mitochondrial function while its overex-
pression increases mitochondrial function, suggesting EglN2’s role in
mitochondrial regulation may be partially independent of its enzy-
matic activity. Further evidence of this is the finding that overexpres-
sion of EglN2 wild-type (WT) or catalytic dead mutant (H358A) in
breast cancer cells increases mitochondrial DNA content to similar
levels. These findings suggest that under normoxia condition, EglN2
is an active enzyme affecting its substrate hydroxylation and stabil-
ity. However, during cancer development, cancer cells become
hypoxic with impaired EglN2 enzymatic activity, and EglN2 instead
binds to NRF1 and affects mitochondrial function as a transcriptional
activator. It is also important to point out that hypoxia, by using
other mechanisms than HIF1a accumulation, induces EglN2 and
NRF1 interaction to maintain mitochondrial function. This was
supported by the observation that the interaction between NRF1 and
EglN2 was not mitigated by HIF1a depletion in these cells under
hypoxia. The detailed mechanism underlying hypoxia-induced NRF1
and EglN2 interaction awaits further investigation. Another interest-
ing observation is that HIF1a and ARNT motifs were enriched in
both EglN2 positively and negatively regulated genes, suggesting
that EglN2 might bind DNA via HIF and is involved in some signal-
ing pathways other than mitochondrial functional regulation.
Hypoxia was shown to decrease oxygen consumption in many
cell lines as well as in vivo (Denko, 2008). Our findings suggest that
EglN2 overexpression under hypoxia induces mitochondrial func-
tion, while EglN2 depletion under this condition decreases oxygen
consumption rate. Therefore, it is interesting to observe that even
under hypoxic condition, oxygen consumption and mitochondrial
function are still important for cancer cells. This phenomenon is
supported by several published literatures. For example, glutamine-
driven oxidative phosphorylation is a major means of ATP
production even in hypoxic cancer cells (Fan et al, 2013). Another
example is that mitochondrial enzyme SHMT2 is induced upon
hypoxia and is critical for maintaining NADPH production and
redox balance to support cancer cell growth (Ye et al, 2014). In
addition, previous research shows that hypoxia activates transcrip-
tion via a mitochondria-dependent signaling (Chandel et al, 1998).
▸Figure 6. FDXR regulates mitochondrial function and ERa-positive breast tumorigenesis.A, B qRT–PCR of mRNA (A) and mitochondrial DNA (B) from T47D cells infected with lentivirus encoding either FDXR shRNA (434, 435) or control (Ctrl) shRNA followed
by hypoxia treatment (5% O2).
C–F Immunoblot of cell lysates (C), qRT–PCR of mitochondrial DNA (D), measurement of oxygen consumption rate (E), and anchorage-independent growth assay (F)
from T47D cells infected with lentivirus encoding either HA-FDXR or control (Ctrl) followed by another infection with lentivirus encoding either EglN2 shRNA (326)
or control () shRNA.
G Cell proliferation assay for T47D cells infected with lentivirus encoding either FDXR shRNA (434, 435) or control (Ctrl) shRNA as a function of time.
H Representative bioluminescence imaging from Day 3 and Day 31 post-implantation of cancer cells injected orthotopically into the mammary fat pads as indicated.
I Quantitation of imaging studies carried out in (H). See Materials and Methods for normalization description.
J Representative tumor gross appearance at the necropsy.
K Tumor weight plots at the necropsy.
L Unpaired two-sample t-test comparing expression of FDXR in METABRIC datasets between the indicated patient samples.
M Kaplan–Meier OS curves for ERa-positive patients in METABRIC cohorts (Curtis et al, 2012). Patients were rank-ordered and divided into two equal groups (low in
green and high in red), using the FDXR gene expression level.
Data information: Two-tailed Student’s t-test was used to examine the P-values from at least three replicate experiments. Error bars represent SEM. *P < 0.05,
**P < 0.01, ***P < 0.005. NS denotes not significant. See also Fig EV5E.
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Our results suggest that by binding with NRF1 and PGC1a complex,
EglN2 serves to maintain the mitochondrial function under hypoxia
in ERa-positive breast cancer.
It is also intriguing that FDXR, a mitochondrial flavoprotein that
initiates the electron transport for cytochrome p450 receiving elec-
trons from NDAPH, was able to regulate mtDNA levels in breast
cancer cells. One possibility is that our metabolomics analysis
showed the decreased glutamine to glutamate conversion upon
FDXR depletion (Zhang J and Zhang Q, unpublished data). Since
glutamine to glutamate conversion is important for generation of
intermediates important for production of pyrimidine de novo
synthesis (Newsholme et al, 2003; Pearce et al, 2013), FDXR deple-
tion could lead to decreased pyrimidine synthesis and mtDNA
reduction without affecting mitochondrial mass. The other possibil-
ity is that mitochondrial dNTP imbalance has been reported to
decrease mtDNA content in various cells or mouse tissues (Song
et al, 2003; Akman et al, 2008; Lopez et al, 2009). Our results show
that FDXR depletion leads to unbalanced dNTP production (Zhang J
and Zhang Q, unpublished data), which could contribute to the
mtDNA reduction.
Development of EglN2 enzymatic inhibitors can potentially
decrease cyclin D1 and breast tumorigenesis (Zhang et al, 2009;
Zheng et al, 2014). Our study, however, suggests that EglN2’s cata-
lytic-independent function could still contribute to mitochondrial
functions in breast cancer cells, thus pointing to abrogating EglN2
expression as a potentially more effective therapy. With the matur-
ing siRNA/shRNA delivery strategies in vitro and in vivo, as well as
the emerging TALEN or CRISPR technologies, we can manipulate
EglN2 expression in breast cancer in the near future to examine its
therapeutic efficacy. It is worth noting that EglN2 knockout MEFs
does not affect mtDNA or basal OCR phenotype and our unpub-
lished data show that depletion of EglN2 in human mammary
epithelial cells (HMECs) does not affect mtDNA content, which indi-
cates the specificity of EglN2 regulation on mitochondrial function
in breast cancer but not in normal cells. In addition, our current
findings identified some downstream targets of EglN2 (such as
FDXR) that are important for mediating mitochondrial function in
ERa-positive breast cancer. These targets will likely open new
therapeutic avenues to modulate mitochondrial function and breast
tumorigenesis in ERa-positive breast cancer.
Materials and Methods
Cell culture
293FT and MCF-7 cells were cultured in DMEM containing 10%
fetal bovine serum (FBS) plus 1% penicillin/streptomycin (Pen/
Strep). T47D cells were maintained in RPMI medium containing
10% FBS plus 1% Pen/Strep. Following lentivirus infection, cells
were maintained in the presence of hygromycin (200 lg/ml) or
puromycin (2 lg/ml) depending on the vector. All cells were main-
tained at 37°C in 5% CO2 incubator.
Western blot analysis and antibodies
EBC buffer (50 mM Tris pH 8.0, 120 mM NaCl, 0.5% NP-40, 0.1 mM
EDTA, and 10% glycerol) supplemented with complete protease
inhibitor (Roche Applied Biosciences) was used to harvest whole-cell
lysates from 5 × 105 indicated cells for immunoblots. Subcellular
protein fractionation kits were obtained from Thermo Scientific. Cell
lysate concentrations were measured by Bradford assay. Equal
amount of cell lysates was resolved by SDS–PAGE. The experiments
were repeated for three times with similar results. Rabbit EglN2 anti-
body (NB100-310), HIF2a (NB100-122), and HIF1a (NB100-479)
were from Novus Biological. Rabbit anti-cyclin D1 was from
Neomarker. Mouse anti-HIF1a (610958), anti-ARNT (611079), and
anti-cytochrome C (556433) were from BD Bioscience. Antibodies
against vinculin (V9131), a-tubulin (T9026), and MCU (HPA016480)
were from Sigma. Mouse antibody against hemagglutinin (HA,
MMS-101P) was obtained from Covance. Mouse anti-PGC1a anti-
body (St1202) and rabbit anti-PDH Ser293 (AP1062) were from
Calbiochem. Sheep anti-EglN2 antibody (AF6394) was from R&D.
Mouse anti-NRF1 (ab55744), anti-CLPP (ab124822), anti-mitofusin-1
(ab57602), and anti-mitofusin-2 (ab56889) were obtained from
Abcam. Antibodies against AIF (#4642), Bcl-XL (#2762), PDH
(#2784), and VDAC (#4866) were obtained from Cell Signaling. Anti-
COX3 (G2413) was from Santa Cruz Biotechnology. Antibodies
against ND1 (19703-1-AP), ND2 (19704-1-AP), ND5 (55410-1-AP),
COX1 (55071-1-AP), COX2 (55070-1-AP), NDUFA9 (20312-1-AP),
SDHA (14865-1-AP), and UQCRFS1 (18443-1-AP) were from Protein-
tech. Peroxidase-conjugated goat anti-mouse secondary antibody
(31430) and peroxidase-conjugated goat anti-rabbit secondary anti-
body (31460) were purchased from Thermo Scientific.
Plasmids
Full-length FLAG and HA double-tagged EglN2 was amplified by
PCR with a 50 primer that introduced a FLAG tag and an HA tag
with a BamHI site and a 30 primer that introduced an EcoRI site. The
PCR product was digested with BamHI and EcoRI and cloned
into the pBABE-puro vector cut with these two enzymes. pLenti6
FLAG-EglN2 was described previously (Koivunen et al, 2012).
pSG5-TETr-EglN2 fusion was created by ligating the full-length
EglN2 ORF (amplified with 50 BamHI site and 30 EcoRI site) into the
pSG5-TETr empty vector cut with BamHI/EcoRI. pSG5-TETr-CDK2,
pSG5-TETr-E2F1, and pUHC 13-3 reporter were described previ-
ously (Kim & Kaelin, 2001). GST-NRF1 and HA-NRF1 were
described previously (Wang et al, 2006). The full-length FOXO3a
insert was cut with BamHI and NotI and ligated into pGex 4T.2
vector cut with these two enzymes to make the construct for GST-
FOXO3a. Full-length HA-tagged NRF1 was amplified by PCR with a
50 primer that introduced a BamHI site and an HA tag and a 30
primer that introduced a NotI site. The PCR product was digested
with BamHI and NotI and cloned into pLenti-UBC-pGK-Hyg (a
modified version of pLL3.7) vector cut with these two enzymes.
Full-length HA-tagged FDXR was amplified by PCR with a 50 primer
that introduced an XbaI site and an HA tag and a 30 primer that
introduced an XhoI site. The PCR product was digested with XbaI
and XhoI and cloned into pLenti CMV GFP vector (addgene)
digested with XbaI and SalI.
Virus production and infection
293FT packaging cell lines were used for lentiviral amplification.
Lentiviral infection was carried out similarly as previously described
The EMBO Journal Vol 34 | No 23 | 2015 ª 2015 The Authors
The EMBO Journal EglN2 regulates mitochondrial function Jing Zhang et al
2966
(Zhang et al, 2009). Briefly, post-transfection with Lipofectamine
2000, viruses were collected twice after 48 and 72 h. After passing
through 0.45-lm filters, appropriate amount of viruses was used to
infect target cells in the presence of 8 lg/ml polybrene. Subse-
quently, target cell lines underwent appropriate antibiotic selection.
siRNAs and lentiviral shRNA vectors
Non-targeting siRNA no. 2 was obtained from Dharmacon (cata-
logue number: D0012100220). EglN2 (1) and EglN2 (4) siRNAs were
described previously (Zhang et al, 2009). NRF1 smart pool siRNA
was obtained from Dharmacon (catalogue number: L-017924).






Lentiviral EglN2, HIF1a, ARNT, and FDXR shRNAs were
obtained from Broad Institute TRC shRNA library. Target sequences













Total RNA was isolated with RNeasy mini kit (Qiagen) from 2 × 105
indicated cells. First-strand cDNA was generated with the iScript
cDNA synthesis kit (Bio-Rad). Real-time PCR was performed in
triplicate as described previously (Zhang et al, 2009). Real-time
RT–PCR primers used in this study are included in Table EV6. The
experiments were repeated for three times with similar results.
GST protein purification and GST pull-down
Glutathione S-transferase plasmids were transformed with BL21
competent cells. Single colonies were picked from above and
cultured in 50 ml LB medium containing ampicillin. After overnight
culture, 5 ml LB medium was diluted in 500 ml LB medium for
shaking at 37°C for 2–3 h until OD600 of 0.8–1.0 was reached.
0.2 mM IPTG was added to induce GST protein production for 4 h
before harvesting pellets. Bacteria lysates were disrupted by the
nanodebee homogenizer. Cleared bacteria lysates were purified by
using glutathione–Sepharose 4B beads. About 20 ll of GST suspen-
sion proteins was incubated with either in vitro translated protein in
500 ll NETN buffer or cell lysates. After overnight incubation,
bound complexes were washed with NETN buffer 8 times followed
by boiling in SDS loading buffer and SDS–PAGE.
Immunoprecipitation
Cells were lysed in EBC lysis buffer supplemented with complete
protease inhibitors (Roche Applied Bioscience). The lysates were
clarified by centrifugation and then mixed with primary antibodies
or 3F10 HA-conjugated beads (Roche Applied Bioscience) overnight.
For primary antibody incubation overnight, cell lysates were incu-
bated further with protein G sepharose beads (Roche Applied
Bioscience) for 2 h. The bound complexes were washed with NETN
buffer for 8 times and were eluted by boiling in SDS loading buffer.
Bound proteins were resolved in SDS–PAGE followed by Western
blot analysis. The experiments were repeated for three times with
similar results.
Luciferase reporter assay
For TETr-fusion protein transcription assay, subconfluent 293FT or
T47D cells (200,000 cells/24-well plate) were transiently transfected
with pCMV-Renilla (30 ng), 100 ng of pUHC13-3 reporter plasmid
and indicated plasmids encoding TETr-fusion plasmids or empty
vector (100 ng unless indicated otherwise). Forty-eight hours after
transfection, luciferase assay were performed as described previ-
ously (Kim & Kaelin, 2001). The experiments were repeated for
three times with similar results.
Cell proliferation assays
T47D cells were plated, in triplicate, in 96-well plates (3,000 cells/
well) in appropriate growth medium. At indicated time points, cells
were replaced with 90 ll fresh growth medium supplemented with
10 ll MTS reagents (Promega) followed by incubation at 37°C for
2 h. The OD absorbance value was measured at 490 nm using a
96-well plate reader. The experiments were repeated for three times
with similar results.
Oxygen consumption rate (OCRs) measurement in cells
The extracellular oxygen consumption was determined by OCRs
using the Seahorse XF24 extracellular flux analyzer (Seahorse
Bioscience). About 1 × 105 of indicated cells were seeded into XF24
cell culture microplate 24 h before the assay. For OCR, the baseline
mitochondrial respiration was established by recording extracellular
oxygen concentration at several time points. Respiration not linked
to mitochondrial ATP synthesis was measured after adding 1 lM
oligomycin through an automated injection port of XF24. Uncoupled
respiration measured was obtained after adding 1 lM FCCP. Hansa-
tech oxygen electrode was used to measure the total cellular oxygen
consumption of indicated cell lines under hypoxia (for T47 cell
lines: 2 × 106, for MCF-7 cell lines: 1 × 106) according to the manu-
facturer’s instructions and previous literature (Zhang et al, 2012).
For each experiment, equal numbers of cells suspended in 1 ml
respiration buffer were pipetted into the calibrated oxygen electrode
chamber and the temperature was maintained at 37°C for measure-
ment. The experiments were performed for three times with similar
results.
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Measurement of mitochondrial DNA content
Archive-quality DNA was extracted with Gentra Puregene cell kit
(Qiagen) according to the manufacturer’s instructions from 2 × 105
indicated cells. Mitochondrial DNA content was measured by the
relative values of mtDNAs (within D-loop, Cox1, or mt-ND2) versus
nuDNA (within the TBP nuclear regions on chromosome 6) by qRT–
PCR (Moiseeva et al, 2009). See Table EV6 for the primer sequences
used for nuDNA, D-loop, Cox1, and mt-ND2. The experiments were
repeated for three times with similar results.
ChIP, ChIP-Seq, and gene expression microarray analysis
ChIP was performed with HA antibody (Santa Cruz) or NRF1 anti-
body (Abcam, a55744) as previously described for T47D (3 × 108)
cells (Chen et al, 2008). The ChIP-Seq library was prepared using
ChIP-Seq DNA sample preparation kit (Illumina) according to the
manufacturer’s instructions. All of ChIP-Seq peaks were identified
by using MACS package with a P-value cutoff of 1 × 105 (Zhang
et al, 2008). For gene expression microarray, cells (2 × 105) were
treated with indicated conditions followed by total RNA extraction
by using RNeasy kit with on column DNase digestion (Qiagen);
Biotin-labeled cRNA was prepared from 1 mg of total RNA,
fragmented, and hybridized to Affymetrix human gene 1.0 ST
expression array. All gene expression microarray data were normal-
ized and summarized using RMA. The differentially expressed genes
were identified using Limma. The ChIP-Seq and microarray data
discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series Acces-
sion Number GSE59937.
Anchorage-independent growth assay
Cells were plated at a density of 5,000 cells per ml in complete
medium with 0.4% agarose, onto bottom layers composed of
medium with 1% agarose followed by incubation at 4°C for 10 min.
Afterward, cells were moved to 37°C incubator. For every 4 days,
three drops of complete media were added onto the plate. After
2 weeks, the extra liquid on the plate was aspirated, 1 ml medium
was added into each well, and colonies were stained by 100 lg/ml
iodonitrotetrazoliuim chloride solution. Cell culture plates were put
back in the incubator overnight followed by counting of foci
number. The experiments were repeated for three times with similar
results.
Orthotopic tumor growth
Six-week-old female NOD/SCID gamma mice (NSG, Jackson labora-
tory) were randomly distributed for xenograft studies. FDXR knock-
down (sh434 or sh435) and control cells were injected bilaterally in
order to have fair comparison. Approximately 4 × 106 viable T47D
breast cancer cells were resuspended in 100 ll growth factor
reduced matrigel (BD biosciences) and injected orthotopically into
the mammary gland as described previously (Zhang et al, 2009).
Bioluminescence imaging was performed as described previously
(Zhang et al, 2009). Seven mice were included in the group (FDXR
sh434/Ctrl) and six mice were included in the group (FDXR sh435/
Ctrl). For each mouse, total photons from mammary fat pad injected
with cells expressing FDXR shRNA were divided by total photons
from the contralateral fat pad with cells expressing control shRNA
and normalized to the ratio for that mouse on the day 3 post-
implantation of cancer cells. Mice were sacrificed 4 weeks after the
first imaging, as specified in the figure legends. The total mass of
tumors was presented as mean  SEM and evaluated statistically
using the unpaired two-tail Student’s t-test. All animal experiments
were complied with National Institutes of Health guidelines and
were approved by the University of North Carolina at Chapel Hill
Animal Care and Use Committee.
Statistical analysis
The unpaired two-tail Student’s t-test was used for experiments
comparing two sets of data. Data represent mean  SEM from three
independent experiments. *, **, and *** denote P-value of < 0.05,
0.01, and 0.005, respectively. NS denotes not significant.
Expanded View for this article is available online:
http://emboj.embopress.org
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